Symbiotec Pharmalab IPO Day 2: GMP signals 34% upside — Should you subscribe?

Symbiotec Pharmalab IPO enters its second day with 80% subscription and a 34% GMP, indicating strong listing expectations. The Rs 1,757 crore issue offers specialised API and biotechnology exposure, while proceeds will reduce debt. However, premium valuations and moderate return ratios warrant caref…